Search

Analysts recommend these 2 stocks despite their losses

Table of Contents

One of the main objectives that all people have before entering the world of investments is to buy good quality securities at a relatively low price for this to bring good economic returns. The key to achieving this lies in identifying which assets keep a lower price than what they are really worth. There is a wide variety of assets with declining prices; however, it is necessary to study these opportunities and assess which ones have solid fundamentals to be acquired.

Due to the vast experience of Wall Street analysts, they currently recommend mainly two assets that should capture the interest of investors because they offer attractive bargains. Even though both stocks had significant losses, around 50% in the last year, they are rated as “Strong Buys”.

Adtran Inc.

Adtran is an Alabama-based company specialized in telecommunications and fiber networks. It offers a variety of products adaptable to existing network infrastructures, including voice, data, video, and internet communications.

The company operates globally in partnership with service providers, facilitating scalable management of services to connect people, places, and devices. With offices in several countries, Adtran’s portfolio ranges from network infrastructure to residential and enterprise solutions, cloud software, and support services.

Despite its global presence, Adtran’s stock has seen a 59% drop year-to-date due to disappointing results, such as Q2 results that showed a 90% year-over-year increase in revenue, but still fell short of expectations by $2.3 million.

Despite these difficulties, analyst Mike Genovese of Rosenblatt defends the company, arguing that the stock is affordable, that it has won more Huawei replacement business than any other, and anticipates revenue growth in 2024. Genovese rates the company’s stock a “Buy” with a price target of $11 per share, implying an upside potential of about 44% in a year.

Similarly, in a recent report, Needham & Company LLC has reaffirmed its “Buy” rating on Adtran stock, setting a price target of $15 per share, representing a potential upside of 97.89% from the previous close.

Other analyses have also been issued, Northland Securities set a $13 price target, while Argus adjusted its price target from $30 to $16. TheStreet and StockNews.com lowered ratings to “d+” and “sell” respectively, and Rosenblatt Securities lowered its price target to $16, maintaining a “buy” rating.

Adtran shares started the week at $7.58, with a market cap of $596.17 million. With a P/E of -14.69 and a beta of 1.39, the stock has a 50-day moving average price of $9.97 and a 200-day moving average price of $12.48. In the latest quarterly report, Adtran beat analysts’ consensus estimates with earnings per share of $0.09, albeit with a negative net margin of 2.96%.

Analysts anticipate that Adtran could post -0.05 earnings per share for the current year. Moreover, 80.32% of the company’s stock is owned by institutional investors, which include Intrust Bank NA, DnB Asset Management AS, Capstone Investment Advisors LLC, Koesten Hirschmann & Crabtree INC. and Envestnet Asset Management Inc.

IGM Biosciences

Biomedical research company IGM Biosciences stands out for its focus on IgM antibody drugs, overcoming the limitations of existing IgG antibodies. The company has developed a series of IgM-based “super antibodies” that form the basis of a new generation of advanced drug candidates.

With seven active lines of research, six of which have advanced to Phase 1 clinical trials, IGM is focused on monotherapies and combination therapies for different types of cancer. Its lead candidate, Aplitabart, has shown promising results in trials, especially in combination with other drugs in cases such as colorectal cancer and acute myeloid leukemia.

In addition, imvotamab, a potential treatment for autoimmune diseases, has obtained FDA approval for Phase 1b clinical trials in systemic lupus erythematosus and rheumatoid arthritis.

Despite positive developments and results in its research, IGM Biosciences shares have experienced a 54% decline over the year. The company reported its financial results for the third quarter ended August 3, 2023, and were met with surprise and disappointment. IGM reported a loss per share of $1.43, significantly below analysts’ consensus estimates that expected a loss of $0.03, representing 2.14%.

This unexpected loss has generated concern among investors expecting a positive turnaround. In addition, the low return on investment and a negative net margin of 14,007.47% have accentuated the disappointment surrounding the results.

However, among the disappointing figures, an increase in IGM Biosciences’ revenues compared to the same period last year stands out. During this quarter, the company generated $0.45 million in revenue, representing a remarkable 22.4% year-over-year increase. While this growth is a bright spot amidst the challenging situation, uncertainty arises as to its long-term sustainability.

In parallel, internal share purchases by senior management have attracted attention. M Kathleen Behrens, a director of the company, purchased 112,500 shares at an average price of $8 per share, showing confidence in IGM Biosciences’ prospects despite unfavorable financial results. Director Jakob Haldor Topsoe also purchased 3,500 shares, highlighting the company’s transparency and regulatory compliance.

These internal purchases can generate confidence among both existing shareholders and potential investors, suggesting solid support for the company’s future growth. Despite temporary hurdles, IGM Biosciences is at a pivotal point as it seeks to address its profitability challenges and maintain investor confidence in a highly competitive biotech environment.

Stay up to date with the latest news of the financial world with our NewsFlight newsletter.

(Information in this post is for general informational purposes only. It cannot and should not be considered as suggestions or recommendations regarding investing or financial decisions.)

Ready to start investing?

Invest in stocks, ETFs, and complex products from US and global exchanges, all commission-free. Start with as little as €5!

Financial news and market insights

Banking sector sell-off

JPMorgan beats profits estimates but misses income expectations. Salesforce plans a big acquisition, while Tesla to layoff 10% of workforce.

Recommended articles

Invest in what really matters to you

Whether it’s renewable energy or the latest IT giant,
invest in it with no commissions on FlexInvest.